COVID-19 Resources (Updated April 24)

Stuck at home? Connect with your fellow patients online! We have several formats available for online support, including oneGRAVESvoice (a collaboration between the GDATF, Horizon Therapeutics, and rareLife solutions), the GDATF's online support forum, and our closed Facebook group (click Join/Visit in the ...

COVID-19 Resources (Updated April 24)

Stuck at home? Connect with your fellow patients online! We have several formats available for online support, including oneGRAVESvoice (a collaboration between the GDATF, Horizon Therapeutics, and rareLife solutions), the GDATF's online support forum, and our closed Facebook group (click Join/Visit in the ...

Tepezza FDA Approval (teprotumumab-trbw)

Jan. 21, 2020

BREAKING NEWS: The FDA has approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease. Wiley Chambers, M.D., deputy director of the Division of Transplant and Ophthalmology Products in the FDA’s Center for Drug Evaluation and Research noted, “Today’s approval marks an important milestone for the treatment of thyroid eye disease. Currently, there are very limited treatment options for this potentially debilitating disease. This treatment has the potential to alter the course of the disease, potentially sparing patients from needing multiple invasive surgeries by providing an alternative, non surgical treatment option.” Read more from the FDA regarding research results, adverse reactions, and the FDA's review process.

Neuropsychiatric Symptoms and Graves'

July 2, 2019

If you enjoyed the GDATF's patient bulletin "What's Wrong With Me? I'm Not Myself Anymore", then you won't want to miss the sequel! "A survey study of neuropsychiatric complaints in patients with Graves’ disease: A reassessment of self-reported symptoms and current practice 20 years later" is now available as an e-manuscript that is free with Kindle Unlimited or $2.99 with Amazon. Many thanks to Dr. James Arruda for conducting this ...